| Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'13 | Sep'12 | Sep'11 | Sep'10 |
|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||
Net income (loss) | ||||||||
-392 | 1,590 | 1,947 | 334 | -353 | - | - | - | - |
Net loss | ||||||||
- | - | - | - | - | -8,727 | -4,303 | 1,351 | 3,234 |
Adjustments to reconcile net income (loss) to net cash: | ||||||||
Stock compensation expense | ||||||||
362 | 457 | 456 | 698 | 459 | 417 | 935 | 563 | 329 |
Foreign exchange loss (gain) | ||||||||
-44 | -17 | 19 | -143 | -70 | 4 | -30 | 0 | - |
Depreciation and amortization | ||||||||
1,420 | 1,257 | 1,238 | 1,267 | 1,196 | 1,596 | 1,669 | 1,233 | 1,040 |
Provision for doubtful accounts and sales returns | ||||||||
15 | 63 | 29 | - | - | - | - | - | - |
Change in reserves | ||||||||
- | - | - | - | - | 6 | 76 | - | - |
Provision for doubtful accounts and sales returns | ||||||||
- | - | - | - | - | - | - | 26 | 1 |
Inventory reserves | ||||||||
- | - | - | - | - | - | - | 0 | - |
Deferred income taxes | ||||||||
282 | -1,715 | -2,677 | 57 | - | -120 | 166 | 128 | 303 |
Contingent consideration adjustment | ||||||||
- | - | - | - | - | 0 | -17 | -95 | - |
Disposal loss (gain) | ||||||||
7 | 0 | -60 | 4 | 178 | 87 | 0 | - | - |
Non-cash R&D services | ||||||||
- | 166 | - | - | - | - | - | - | - |
Non-cash R&D services | ||||||||
- | - | 306 | 0 | - | 51 | 41 | 39 | - |
Impairment of long-lived assets | ||||||||
0 | 182 | 0 | - | - | - | - | - | - |
Pension expense | ||||||||
- | - | - | - | 318 | - | - | - | - |
Provision for inventory reserves | ||||||||
- | - | - | - | 137 | - | - | - | - |
Other | ||||||||
-67 | 11 | -113 | -326 | -209 | - | - | - | - |
Impairment of goodwill and long-lived assets | ||||||||
- | - | - | - | - | 6,829 | 2,284 | 0 | - |
Other changes in assets and liabilities: | ||||||||
Accounts receivable, net | ||||||||
152 | 788 | -91 | 271 | 196 | -1,822 | 2,107 | -497 | 1,689 |
Unbilled receivables | ||||||||
1,469 | -96 | - | - | - | - | - | - | - |
Contract assets | ||||||||
83 | 0 | 109 | - | - | - | - | - | - |
Inventories | ||||||||
705 | -216 | 610 | 1,080 | 365 | -132 | 134 | 153 | -198 |
Costs in excess of billings and unbilled receivables | ||||||||
- | - | - | 310 | -283 | 198 | 1,121 | -273 | -195 |
Prepaid expenses and other assets | ||||||||
162 | -202 | -243 | -8 | 346 | -100 | 574 | 175 | 64 |
Accounts payable | ||||||||
161 | -10 | 748 | -176 | 304 | -364 | 338 | 151 | - |
Accrued expenses and other liabilities | ||||||||
200 | 295 | -218 | 368 | -145 | 29 | 470 | 599 | - |
Contract liabilities | ||||||||
-89 | 112 | - | - | - | - | - | - | - |
Deferred revenue | ||||||||
- | - | -110 | - | - | - | - | - | - |
Deferred revenue | ||||||||
- | - | - | 129 | 9 | -178 | 694 | 0 | - |
Net cash from operating activities | ||||||||
- | - | - | - | 836 | - | - | - | - |
Accounts payable and accrued expenses | ||||||||
- | - | - | - | - | - | - | - | 845 |
Income taxes payable | ||||||||
- | - | - | - | - | - | - | - | -894 |
Net cash from operating activities | ||||||||
-508 | 2,129 | 1,488 | 2,109 | - | 1,701 | 693 | 3,892 | 3,109 |
Cash flows from investing activities: | ||||||||
Proceeds from sale of property, plant and equipment | ||||||||
- | - | 3 | 4 | 244 | 80 | 0 | - | - |
Purchases of property, plant and equipment | ||||||||
893 | 2,244 | 913 | 1,514 | 1,310 | 544 | 1,018 | 1,543 | 363 |
Purchases of intangibles | ||||||||
- | 73 | 69 | 102 | - | - | - | - | - |
Net cash from investing activities | ||||||||
- | - | - | - | -1,066 | - | - | - | - |
Cash paid for acquisition of Biomedical Technologies | ||||||||
- | - | - | - | - | - | - | -300 | -4,002 |
Net cash from investing activities | ||||||||
-893 | -2,317 | -979 | -1,612 | - | -464 | -1,018 | -1,843 | -4,366 |
Cash flows from financing activities: | ||||||||
Proceeds from issuance of common stock | ||||||||
14 | 17 | 17 | 16 | 12 | 21 | 63 | 135 | 271 |
Proceeds from (payments of) long-term debt | ||||||||
- | - | -621 | - | - | - | - | - | - |
Repurchase of common stock | ||||||||
3,249 | 0 | - | - | - | 0 | 1,857 | 0 | - |
Payment of debt issuance costs | ||||||||
- | - | - | - | - | 0 | 56 | 0 | - |
Net proceeds from issuance of convertible notes | ||||||||
- | - | - | 840 | 613 | - | - | - | - |
Principal payments on capital leases | ||||||||
40 | 93 | 106 | 118 | 147 | 76 | 0 | - | - |
Proceeds from (payments of) line of credit, net | ||||||||
929 | 0 | - | - | - | - | - | - | - |
Proceeds from (payments of) equipment line of credit, net | ||||||||
484 | 742 | 0 | 545 | 2,501 | - | - | - | - |
Net cash from financing activities | ||||||||
- | - | - | - | -2,265 | - | - | - | - |
Proceeds from debt refinancing | ||||||||
- | - | - | - | - | - | - | - | 626 |
Proceeds from long-term debt | ||||||||
2,000 | 0 | - | - | - | - | - | - | 4,000 |
Proceeds from short and long-term debt | ||||||||
- | - | - | - | - | 0 | 3,000 | 0 | - |
Payments of long-term debt | ||||||||
763 | 533 | - | 349 | 5,244 | 2,165 | 1,860 | 1,858 | 2,058 |
Deferred financing costs incurred | ||||||||
- | - | - | - | - | - | - | - | -146 |
Preferred stock dividends paid | ||||||||
- | - | - | - | - | - | - | 79 | 445 |
Net cash from financing activities | ||||||||
-625 | 133 | -710 | 934 | - | -2,220 | -711 | -1,803 | 2,247 |
Effect of exchange rates on cash and cash equivalents | ||||||||
-33 | -33 | - | - | - | - | - | - | - |
Net change in cash and cash equivalents | ||||||||
-2,059 | -88 | - | - | - | - | - | - | - |
Effect of exchange rates on cash and cash equivalents | ||||||||
- | - | 9 | -119 | -52 | 6 | -28 | 121 | 16 |
Net change in cash and cash equivalents | ||||||||
- | - | -192 | 1,312 | -2,547 | -978 | -1,064 | 367 | 1,007 |